The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics. (Q49658111)
Jump to navigation
Jump to search
scientific article published on 13 December 2017
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics. |
scientific article published on 13 December 2017 |
Statements
1 reference
The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics. (English)
1 reference
Kenneth W Mahaffey
1 reference
Bernard Zinman
1 reference
Christopher P Cannon
1 reference
Meg J Jardine
1 reference
Bruce Neal
1 reference
Rajiv Agarwal
1 reference
George L Bakris
1 reference
Barry M Brenner
1 reference
Scott Bull
1 reference
David M Charytan
1 reference
Dick de Zeeuw
1 reference
Robert Edwards
1 reference
Tom Greene
1 reference
Hiddo J L Heerspink
1 reference
Adeera Levin
1 reference
Carol Pollock
1 reference
David C Wheeler
1 reference
John Xie
1 reference
Hong Zhang
1 reference
Mehul Desai
1 reference
Vlado Perkovic
1 reference
CREDENCE study investigators
1 reference
13 December 2017
1 reference
46
1 reference
462-472
1 reference
6
1 reference
1 reference
1 reference
1 reference
Identifiers
1 reference
1 reference
1 reference